{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-24-000614","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2024-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.975923+00:00","generated_at":"2026-06-02T12:07:57.127703+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arcturus Q1 2024 revenue $38M, net loss $26.8M; Kostaive on track for Q3 launch, cash runway through FY2027","bullets":["Q1 2024 revenue $38.0M (down 53% YoY); net loss $26.8M ($1.00/share) vs net income $50.8M ($1.87) in Q1 2023.","Cash $345.3M; runway extends at least three years to Q1 FY2027; expects future CSL milestones.","Kostaive commercialization on track: initial 4M doses delivery in Q3; European MAA decision expected Q3.","Phase 3 pivotal study for ARCT-2303 (XBB.1.5) initiated; ARCT-2138 flu Phase 1 topline data expected Q3.","ARCT-810 (OTC) and ARCT-032 (CF) data updates on July 1, 2024; JP Morgan engaged to monetize ARCALIS JV stake."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-24-000614","json":"https://secwatch.observer/filing/0001193805-24-000614.json","markdown":"https://secwatch.observer/filing/0001193805-24-000614.md","text":"https://secwatch.observer/filing/0001193805-24-000614.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000614/0001193805-24-000614-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000614/e663590_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T12:07:57.127703+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c6393c9347c9f8cb13d132bced685fc292366c7f","claim":"Arcturus Therapeutics Holdings Inc. reported the three months ended March 31, 2024 results: revenue $38.0 million.","evidence_excerpt":"For the three months ended March 31, 2024, revenues were $38.0 million compared with $80.3 million for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1768224/000119380524000614/0001193805-24-000614-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$38.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}